NCT03810742 2023-11-18
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
PharmaEngine
Phase 1 Completed
Clinical Trials
3 trialsNCT00914914 2014-10-28
Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment
CDG Therapeutics, Inc.
Phase 1 Completed
NCT00394446 2008-02-13
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
Myrexis Inc.
Phase 1 Completed